详情页

当前位置：首页 > 详情页

Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.

21| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp [2]Peking Union Medical College, Beijing, China. [2]Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China. [3]State Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. [4]Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, China. [5]Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences &amp [7]Peking Union Medical College, Beijing, China. [6]Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. [7]Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [8]Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. [9]Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China. [10]Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. [11]Cancer Center, People's Hospital, Huhehot, China. [12]Department of Respiratory Medicine, Shanxi Provincial Cancer Hospital, Taiyuan, China. [13]Department of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, China. [14]Department of Respiratory and Critical Care Medicine, Quzhou People's Hospital, Zhejiang, China. [15]Department of Respiratory Medicine, Zhejiang Provincial People's Hospital, Zhejiang, China. [16]Department of Respiratory Medicine, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Zhejiang, China. [17]Department of Respiratory Medicine and Critical Care Medicine, Zhuji People's Hospital, Zhejiang, China. [18]Department of Oncology, Renji Hospital, Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. [19]Department of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. [20]Department of Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.

出处：

DOI：

ISSN：

关键词： advanced lung cancer immune checkpoint inhibitors immune-related adverse events real-world data

摘要：

Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune-related adverse events (irAEs) remain poorly understood, especially in a real-world setting.A multicenter observational study was conducted. Medical records of lung cancer patients treated with ICIs at 26 hospitals from January 1, 2015, to February 28, 2021, were retrieved. Types of ICIs included antiprogrammed cell death 1 or antiprogrammed cell death ligand 1 (PD-L1) monotherapy, anticytotoxic T-lymphocyte antigen-4 monotherapy, or combination therapy.In total, 1905 patients with advanced lung cancer were evaluated. The median age was 63 (range 28-87) years, and the male/female ratio was 3.1:1 (1442/463). The primary histological subtype was adenocarcinoma (915). A total of 26.9% (512/1905) of the patients developed 671 irAEs, and 5.8% (110/1905) developed 120 grade 3-5 irAEs. Median duration from ICI initiation to irAEs onset was 56 (range 0-1160) days. The most common irAEs were thyroid dysfunction (7.2%, 138/1905), pneumonitis (6.5%, 124/1905), and dermatological toxicities (6.0%, 115/1905). A total of 162 irAEs were treated with steroids and 11 irAEs led to death. Patients with positive PD-L1 expression (≥1%) and who received first-line ICI treatment developed more irAEs. Patients who developed irAEs had a better disease control rate (DCR, 71.3% [365/512] vs. 56.0% [780/1145]; p < 0.001).The incidence rate of irAEs was 26.9% in a real-world setting. IrAEs might be related to a better DCR, but clinicians should be more aware of irAE recognition and management in clinical practice.© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2022]版：

大类 | 3 区医学

小类 | 3 区肿瘤学 3 区呼吸系统

最新[2025]版：

大类 | 4 区医学

小类 | 4 区肿瘤学 4 区呼吸系统

JCR分区：

出版当年[2022]版：

Q3 ONCOLOGY Q3 RESPIRATORY SYSTEM

最新[2024]版：

Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY

影响因子： 2.3 最新[2024版] 2.7 最新五年平均 2.9 出版当年[2022版] 3.1 出版当年五年平均 3.223 出版前一年[2021版] 2.3 出版后一年[2023版]

第一作者：

第一作者机构： [1]Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp

通讯作者：

通讯机构： [1]Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp [*1]Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.

文献详情

相关文献